A systematic review of model-based economic evaluations of diagnostic and therapeutic strategies for lower extremity artery disease

Thrombosis and Haemostasis

Volumn 111, Issue 1, 2013, Pages 19-28

  Vaidya, Anil ^a,b   Joore, Manuela A ^a,b   ten Cate Hoek, Arina J ^a   Kleinegris, Marie Claire ^c   ten Cate, Hugo ^c   Severens, Johan L ^d  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

Decision analytic model; Economic evaluation; Lower extremity artery disease; Systematic review

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INOSITOL NICOTINATE; NAFTIDROFURYL; NAFTIDROFURYL OXALATE; PENTOXIFYLLINE;

ARTERY DISEASE; CONVENTIONAL ANGIOGRAPHY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIAGNOSTIC TEST; ECONOMIC ASPECT; HUMAN; LEG ARTERY; MAGNETIC RESONANCE ANGIOGRAPHY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; WALKING;

DECISION ANALYTIC MODEL; ECONOMIC EVALUATION; LOWER EXTREMITY ARTERY DISEASE; SYSTEMATIC REVIEW;

ATHEROSCLEROSIS; CARDIOLOGY; COST-BENEFIT ANALYSIS; DECISION TREES; DISEASE PROGRESSION; HEALTH CARE COSTS; HUMANS; LOWER EXTREMITY; MODELS, ECONOMIC; PERIPHERAL ARTERIAL DISEASE; QUALITY OF LIFE;

EID: 84891839436     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-06-0498     Document Type: Review

References (37)

1. European Stroke O, Tendera M, Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2851-2906.
2. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992; 326: 381-386.
3. Regensteiner JG, Hiatt WR, Coll JR, et al. The impact of peripheral arterial disease on health-related quality of life in the Peripheral Arterial Disease Awareness, Risk, and Treatment: New Resources for Survival (PARTNERS) Program. Vasc Med 2008; 13: 15-24.
4. Migliaccio-Walle K, Caro JJ, Ishak KJ, et al. Costs and medical care consequences associated with the diagnosis of peripheral arterial disease. Pharm Econom 2005; 23: 733-742.
5. Moriarty JP, Murad MH, Shah ND, et al. A systematic review of lower extremity arterial revascularization economic analyses. J Vasc Surg 2011; 54: 1131-1144 e1.
6. Garcia-Altes A, Peiro S. A systematic review of cost-effectiveness evidence of endoscopic saphenous vein harvesting: is it efficient? Eur J Vasc Endovasc Surg 2011; 41: 831-836.
7. Drummond MF, Sculpher MJ, Torrance GW. Methods for the economic evaluation of health care programmes, Oxford University Press; 2005.
8. Pignone M, Saha S, Hoerger T, et al. Challenges in systematic reviews of economic analyses. Ann Int Med 2005; 142: 1073-1079.
9. Philips Z, Ginnelly L, Sculpher M, et al. Review of guidelines for good practice in decision-analytic modelling in health technology assessment. Health Technol Assess 2004; 8: iii-iv, ix-xi, 1-158.
10. Bosch JL, Haaring C, Meyerovitz MF, et al. Cost-effectiveness of percutaneous treatment of iliac artery occlusive disease in the United States. AJR Am J Roentgenol 2000; 175: 517-521.
11. Bosch JL, Tetteroo E, Mali WP, et al. Iliac arterial occlusive disease: cost-effectiveness analysis of stent placement versus percutaneous transluminal angioplasty. Dutch Iliac Stent Trial Study Group. Radiology 1998; 208: 641-648.
12. Coffi SB, Ubbink DT, Dijkgraaf MG, et al. Cost-effectiveness of identifying aortoiliac and femoropopliteal arterial disease with angiography or duplex scanning. Eur J Radiol 2008; 66: 142-148.
13. de Vries SO, Visser K, de Vries JA, et al. Intermittent claudication: cost-effectiveness of revascularization versus exercise therapy. Radiology 2002; 222: 25-36.
14. Guest JF, Davie AM, Clegg JP. Cost effectiveness of cilostazol compared with naftidrofuryl and pentoxifylline in the treatment of intermittent claudication in the UK. Curr Med Res Opin 2005; 21: 817-826.
15. Holler D, Claes C, von der Schulenburg JM. Cost-utility Analysis of Treating Severe Peripheral Arterial Occlusive Disease. Int J Angiol 2006; 15: 25-33.
16. Hunink MG, Wong JB, Donaldson MC, et al. Revascularization for femoropopliteal disease. A decision and cost-effectiveness analysis. J Am Med Assoc 1995; 274: 165-171.
17. Muradin GS, Myriam Hunink MG. Cost and patency rate targets for the development of endovascular devices to treat femoropopliteal arterial disease. Radiology 2001; 218: 464-469.
18. Sculpher M, Michaels J, McKenna M, et al. A cost-utility analysis of laser-assisted angioplasty for peripheral arterial occlusions. Int J Technol Assess Health Care 1996; 12: 104-125.
19. Sigvant B, Henriksson M, Lundin F, et al. Asymptomatic peripheral arterial disease: is pharmacological prevention of cardiovascular risk cost-effective? Eur J Cardiovasc Prevent Rehabil 2011; 18: 254-261.
20. Squires H, Simpson E, Meng Y, et al. A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease. Health Technol Assess 2011; 15: 1-210.
21. Treesak C, Kasemsup V, Treat-Jacobson D, et al. Cost-effectiveness of exercise training to improve claudication symptoms in patients with peripheral arterial disease. Vasc Med 2004; 9: 279-285.
22. Visser K, de Vries SO, Kitslaar PJ, et al. Cost-effectiveness of diagnostic imaging work-up and treatment for patients with intermittent claudication in The Netherlands. Eur J Vasc Endovasc Surg 2003; 25: 213-223.
23. Visser K, Kock MC, Kuntz KM, et al. Cost-effectiveness targets for multi-detector row CT angiography in the work-up of patients with intermittent claudication. Radiology 2003; 227: 647-656.
24. Visser K, Kuntz KM, Donaldson MC, et al. Pretreatment imaging workup for patients with intermittent claudication: a cost-effectiveness analysis. J Vasc Interv Radiol 2003; 14: 53-62.
25. Yin D, Baum RA, Carpenter JP, et al. Cost-effectiveness of MR angiography in cases of limb-threatening peripheral vascular disease. Radiology 1995; 194: 757-764.
26. Weinstein MC, O'Brien B, Hornberger J, et al. Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices--Modeling Studies. Value Health 2003; 6: 9-17.
27. Ambrosetti M, Salerno M, Boni S, et al. Economic evaluation of a short-course intensive rehabilitation program in patients with intermittent claudication. Int Angiol 2004; 23: 108-113.
28. Belcaro G, Nicolaides AN, Agus G, et al. PGE 1 Treatment of Severe Intermittent Claudication (Short-Term Versus Long-Term, Associated with Exercise). Angiology 2000; 51: S15-S26.
29. Duda SH, Tepe G, Bala M, et al. Economic value of thrombolysis with adjunctive abciximab in patients with subacute peripheral arterial occlusion. Pharm Econom 2002; 20: 203-213.
30. Geitung JT, Wikstrom T, Zeuchner J, et al. Cost-effectiveness of colour duplex sonography compared with angiography of the pelvis and lower limb. Eur Radiol 1996; 6: 481-484.
31. Ikeda S, Kobayashi M, Fukuhara S, et al. Cost-effectiveness of Liple (LipoPGE1) for arteriosclerosis obliterans patients in Japan: an economic evaluation using the EQ-5D instrument. Int Angiol 2006; 25: 169-174.
32. Malagoni AM, Vagnoni E, Felisatti M, et al. Evaluation of patient compliance, quality of life impact and cost-effectiveness of a "test in-train out" exercisebased rehabilitation program for patients with intermittent claudication. Circ J 2011; 75: 2128-2134.
33. Ouriel K, Kolassa M, DeWeese JA, et al. Economic implications of thrombolysis or operation as the initial treatment modality in acute peripheral arterial occlusion. Surgery 1995; 118: 810-814.
34. Spronk S, Bosch JL, den Hoed PT, et al. Cost-effectiveness of endovascular revascularization compared to supervised hospital-based exercise training in patients with intermittent claudication: a randomized controlled trial. J Vasc Surg 2008; 48: 1472-1480.
35. van Asselt AD, Nicolai SP, Joore MA, et al. Cost-effectiveness of exercise therapy in patients with intermittent claudication: supervised exercise therapy versus a 'go home and walk' advice. Eur J Vasc Endovasc Surg 2011; 41: 97-103.
36. van Breda A, Graor RA, Katzen BT, et al. Relative cost-effectiveness of urokinase versus streptokinase in the treatment of peripheral vascular disease. J Vasc Intervent Radiol 1991; 2: 77-87.
37. Lee HL, Mehta T, Ray B, et al. A non-randomised controlled trial of the clinical and cost effectiveness of a Supervised Exercise Programme for claudication. Eur J Vasc Endovasc Surg 2007; 33: 202-207.